Clinical Trials
13 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT07502716 2026-03-31
Compassionate Use of Ubamatamab
Regeneron Pharmaceuticals
Available
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT03994627 2024-12-16
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Eli Lilly and Company
Approved for marketing
NCT04225429 2024-10-01
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Ipsen
No longer available
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT05612191 2022-11-28
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
Advenchen Laboratories, LLC
Available
NCT00210665 2017-10-10
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
No longer available
NCT02712567 2016-10-13
SARC021C: A Continuation Study of TH-CR-406/SARC021
Sarcoma Alliance for Research through Collaboration
No longer available
NCT02570412 2015-10-22
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
CytRx
No longer available
NCT01427582 2011-09-01
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
University of Texas Southwestern Medical Center
No longer available